ライフサイエンスコーパス: ganciclovir

1 CMV-seropositive donors (147 maribavir; 156 ganciclovir).

2 adiotracers ((18)F-FHBG) or antiviral drugs (ganciclovir).

3 137 for oral ganciclovir and day +135 for IV ganciclovir).

4 ectively sensitized EBV(+) lymphoma cells to ganciclovir.

5 MV), including some CMV strains resistant to ganciclovir.

6 fewer hematological adverse events than oral ganciclovir.

7 2.0 mg/0.04 ml of twice weekly intravitreal ganciclovir.

8 rly dividing progenitors by exposing them to ganciclovir.

9 achieved with administration of intravenous ganciclovir.

10 ganciclovir oral solution and of intravenous ganciclovir.

11 ion, all of whom responded to treatment with ganciclovir.

12 discontinuation of tacrolimus and high-dose ganciclovir.

13 prophylaxis with 12 versus 24 weeks of oral ganciclovir.

14 om culture isolates, to detect resistance to ganciclovir.

15 nts received early prophylactic therapy with ganciclovir.

16 and independent of prophylactic exposure to ganciclovir.

17 ovir, and in 1 of 6 patients treated with iv ganciclovir.

18 t plus oral ganciclovir, or intravenous (iv) ganciclovir.

19 cluding those resistant to the anti-CMV drug ganciclovir.

20 old increase in the EC50) and susceptible to ganciclovir.

21 n can be eliminated by the administration of ganciclovir.

22 iated with different levels of resistance to ganciclovir.

23 transplantation followed by 28 days without ganciclovir.

24 is not inferior to intravenous therapy with ganciclovir.

25 l valganciclovir 900 mg twice daily, topical ganciclovir 0.15% 5 applications per day, for 6 weeks) w

26 Patients then either received oral ganciclovir (1 g every 8 hr) or continued IV ganciclovir

27 cidence of clinical CMV disease as high-dose ganciclovir (1 gm three times a day for 3-6 months) in p

28 experiment, a cohort of MCMV+ mice received ganciclovir (10 mg/kg/day subcutaneously) following ceca

29 the most common first-line agents used were ganciclovir (100% and 96.2%) and valganciclovir (23.1%)

30 ntion of CMV disease were compared with oral ganciclovir (1000 mg three times daily) in 303 CMV-seron

31 Of the 500 patients (295 ganciclovir, 205 valganciclovir), 22 patients (4.4%) dev

32 ganciclovir (450 mg/day) was as effective as ganciclovir (3 g/day) for prophylaxis of CMV disease aft

33 ed the effectiveness of three months of oral ganciclovir (3 g/day) versus low-dose valganciclovir (45

34 uced resistance to foscarnet, acyclovir, and ganciclovir (3-, 14-, and 3-fold increases in the 50% ef

35 roup (R-/D+) than patients who received oral ganciclovir (33.3%, P=0.10).

36 ndomized (1:1) to receive either intravenous ganciclovir (5 mg/kg twice daily for 5 days), followed b

37 re treated with intraperitoneal injection of ganciclovir (50 mg/kg) did not develop teratomas when co

38 ganciclovir (1 g every 8 hr) or continued IV ganciclovir (6 mg/kg once per day on Monday-Friday of ea

39 All were treated with high-dose intravenous ganciclovir (7.5-10 mg/kg/12 hr) or oral valganciclovir

40 pted an intensive strategy that consisted of ganciclovir administered before transplantation (5 mg/kg

41 Intravenous ganciclovir administered for 6 weeks improves hearing ou

42 Ablation of the GFP+ cells with chronic ganciclovir administration significantly arrested tumour

43 enografts were treated with adenoviruses and ganciclovir, all animals showed decreased tumor burden a

44 methyl ethers gave the acyclic acyclovir and ganciclovir analogues.

45 Other than ganciclovir and alpha interferon (IFN-alpha) prophylaxis

46 that hypoxia increased the cell toxicity of ganciclovir and azidothymidine in PEL cells but had no s

47 (thymidine kinase), which can phosphorylate ganciclovir and azidothymidine, respectively.

48 ate and quantify the phosphorylated forms of ganciclovir and azidothymidine, we found that PEL cells

49 plication that had occurred was inhibited by ganciclovir and by neutralizing antibodies against gB.

50 Mutations conferring ganciclovir and cidofovir resistance were detected in CM

51 and I726T conferred a borderline decrease in ganciclovir and cidofovir susceptibility, while Q578L an

52 delivery system was initially reported using ganciclovir and cyclic cidofovir as the prototype compou

53 tion (median time of onset day +137 for oral ganciclovir and day +135 for IV ganciclovir).

54 (if possible): ganciclovir dose escalation, ganciclovir and foscarnet combination, and adjunct thera

55 tion in which viral mutations that conferred ganciclovir and foscarnet resistance had evolved sequent

56 Q578L and G841S conferred slightly decreased ganciclovir and foscarnet susceptibility.

57 ed in 3 of 32 patients (9.3%) receiving oral ganciclovir and in 4 of 32 patients (12.5%) receiving IV

58 litis are oral corticosteroids, intravitreal ganciclovir and laser photocoagulation or vitrectomy.

59 rable efficacy of treatment with intravenous ganciclovir and oral valganciclovir for cytomegalovirus

60 Ganciclovir and PFA also prevented most valproate-induce

61 The anti-viral agents ganciclovir and phosphonoformic acid (PFA) blocked valpr

62 were no significant differences between the ganciclovir and placebo groups in duration of mechanical

63 such as the anti-herpes drugs Aciclovir and Ganciclovir and the anti-cancer drug Clofarabine are now

64 Ganciclovir and valganciclovir are highly effective anti

65 UL97 mutations confer resistance to ganciclovir and valganciclovir, and a UL54 mutation conf

66 rotein of which, respectively, phosphorylate ganciclovir and zidovudine to toxic moieties.

67 Intravenous ganciclovir and, increasingly, oral valganciclovir are n

68 nd was treated alternatively with acyclovir, ganciclovir, and foscavir.

69 treated with a ganciclovir implant plus oral ganciclovir, and in 1 of 6 patients treated with iv ganc

70 n of individual antiviral agents (acyclovir, ganciclovir, and valganciclovir) with outcomes in high-r

71 Acyclovir and ganciclovir are both effective for universal prophylaxis

72 phoma cells in vitro to apoptosis induced by ganciclovir, arginine butyrate in combination with ganci

73 udy does not support routine clinical use of ganciclovir as a prophylactic agent in patients with sep

74 ractices were consistent and mainly involved ganciclovir as first-line agent and foscarnet as second-

75 patients from 1996 to 2000 who received oral ganciclovir as preemptive therapy.

76 EA-D during coexpression or to phosphorylate ganciclovir, as measured by an in-cell activity assay.

77 al load, acute graft-versus-host disease, or ganciclovir-associated neutropenia.

78 Patients were initially given IV ganciclovir at a dose of 6 mg/kg per day from days 1 to

79 rmore, treatment of these chimeric mice with ganciclovir at the time of inoculation led to prolonged

80 ing prophylaxis was also reduced with higher ganciclovir AUC (median predicted incidence, 20% and 10%

81 tion in pediatric LT recipients managed with ganciclovir-based preemptive therapy (PET).

82 Ganciclovir blocks MCMV reactivation, thus preventing ab

83 entiviral vector genomes upon treatment with ganciclovir, but not with vehicle control.

84 ve to treatment with the nucleoside analogue ganciclovir by using a bicistronic construct coexpressin

85 AdV-TK followed by ganciclovir can be administered safely to children with

86 duction with 14 days of IV ganciclovir, oral ganciclovir can be as effective as IV ganciclovir for lo

87 lex virus thymidine kinase (HSV-TK) cDNA and ganciclovir can elicit cytotoxicity to transgene-express

88 l solution provides plasma concentrations of ganciclovir comparable to those achieved with administra

89 were approximately 50-fold less sensitive to ganciclovir compared with cultures of 100% HSV-TK-expres

90 ment of these mice with the antiviral agent, ganciclovir, conditionally ablates proliferating reactiv

91 were completely eliminated after exposure to ganciclovir, confirming function of the suicide trap.

92 Through puromycin selection and ganciclovir counter-selection, a targeting efficiency of

93 with ganR-CMV had received <6 weeks of prior ganciclovir (current guideline-recommended resistance te

94 eral cytomegalovirus retinitis with systemic ganciclovir decreases the risk of development of seconda

95 The greater systemic exposure to ganciclovir delivered by valganciclovir was associated w

96 Each injection was followed by ganciclovir delivered intravenously every 12 hours for 7

97 because of repeated courses of therapy with ganciclovir derivatives.

98 th critical illness due to sepsis or trauma, ganciclovir did not reduce IL-6 levels and the current s

99 e the incidence of CMV infection and, unlike ganciclovir, does not cause myelosuppression.

100 er reducing immunosuppression (if possible): ganciclovir dose escalation, ganciclovir and foscarnet c

101 correlations between individual exposure to ganciclovir during prophylaxis, with CMV viremia inciden

102 potentials of BVP22 and HVP22 to enhance Etk/ganciclovir (Etk/GCV) suicide gene therapy for neuroblas

103 established (12% with maribavir vs. 8% with ganciclovir: event rate difference of 0.041; 95% CI: -0.

104 eased neutropenia and leukopenia with higher ganciclovir exposure.

105 nsplant CMV prophylaxis regimen consisted of ganciclovir followed by 1 year of valganciclovir.

106 bulin [CMVIG] plus four weeks of intravenous ganciclovir followed by two months of valganciclovir); w

107 ceived a minimum of 14 days of postoperative ganciclovir, followed by monthly CMV PCR monitoring.

108 onducted to evaluate the pharmacokinetics of ganciclovir following oral administration of ganciclovir

109 ived prophylaxis with valganciclovir or oral ganciclovir for 100 days.

110 tomegalovirus (CMV) disease with intravenous ganciclovir for 6 weeks has been shown to improve audiol

111 th standard prophylaxis (n = 45, intravenous ganciclovir for four weeks).

112 (IV) and oral ganciclovir with prolonged IV ganciclovir for long-term prophylaxis of CMV disease in

113 , oral ganciclovir can be as effective as IV ganciclovir for long-term prophylaxis of CMV disease in

114 noninferiority of maribavir compared to oral ganciclovir for prevention of CMV disease was not establ

115 Experience with high-dose ganciclovir for the management of resistant cytomegalovi

116 rospectively in 2 clinical trials evaluating ganciclovir for the treatment of symptomatic congenital

117 omparing oral valganciclovir and intravenous ganciclovir for treatment of cytomegalovirus disease in

118 perior to that of existing antiherpes drugs, ganciclovir (for HCMV) and acyclovir (for HSV-1 and VZV)

119 Mean daily areas under the curve (AUCs) of ganciclovir from valganciclovir and oral ganciclovir wer

120 that in 23 patients treated with intravenous ganciclovir (GCV) (T(1/2) = 1.73 days; P=.63).

121 s can be temporally regulated by the time of ganciclovir (GCV) administration.

122 Ganciclovir (GCV) and acyclovir (ACV) are guanine nucleo

123 y used as a suicide gene in combination with ganciclovir (GCV) and as a nuclear imaging reporter gene

124 13A, found in a clinical specimen, conferred ganciclovir (GCV) and cidofovir resistance but not fosca

125 reatment for 14 days with the antiviral drug ganciclovir (GCV) depleted Dcx-expressing and BrdU-label

126 we show that the FDA-approved antiviral drug ganciclovir (GCV) induces a type I interferon response i

127 covered unexpectedly that the antiviral drug ganciclovir (GCV) inhibits the proliferation of microgli

128 Prophylactic ganciclovir (GCV) is used in high-risk renal transplant

129 Administration of ganciclovir (GCV) kills actively dividing cells expressi

130 emoprophylaxis with valganciclovir (VGCV) or ganciclovir (GCV) on CMV replication and morbidity.

131 into hepatoma cell lines in the presence of ganciclovir (GCV) pro-drug.

132 gene product in combination with the prodrug ganciclovir (GCV) produces a potent toxin, which affects

133 r survival in renal transplant patients, and ganciclovir (GCV) prophylaxis is associated with improve

134 ate SCI and treated with the antiviral agent ganciclovir (GCV) to ablate dividing, reactive, transgen

135 -type mice, were specifically depleted after ganciclovir (GCV) treatment for 14 days.

136 he lytic form of EBV infection combined with ganciclovir (GCV) treatment.

137 tion of prodrugs 5-fluorocytosine (5-FC) and ganciclovir (GCV) was less efficacious than sequential t

138 blation phase induced by the HSVtk pro-drug, ganciclovir (GCV), oocyte numbers declined due to a disr

139 Interestingly, ganciclovir (GCV), the first line of therapy for human c

140 H) to evaluate the efficacy of HDACI and the ganciclovir (GCV)-mediated anticancer effect contributed

141 apeutic gene in conjunction with the prodrug ganciclovir (GCV).

142 equent altered susceptibility to the prodrug ganciclovir (GCV).

143 ex virus thymidine kinase type 1 (HSVtk) and ganciclovir (GCV).

144 n of osteoblast lineage after treatment with ganciclovir (GCV).

145 g HSCs susceptible to killing in response to ganciclovir (GCV).

146 ion in plasma was significantly lower in the ganciclovir group (12% [10 of 84 patients] vs 39% [28 of

147 and 28.6% (6/21) of the patients in the oral ganciclovir group (P>0.20).

148 was -0.79 log10 units (-2.06 to 0.48) in the ganciclovir group and -0.79 log10 units (-2.14 to 0.56)

149 The ganciclovir group had more median VFDs in both the inten

150 for the valganciclovir group versus the oral ganciclovir group or patients without CMV infection (P>0

151 o group, P = .76), or mortality (12% for the ganciclovir group vs 15% for the placebo group, P = .54)

152 econdary bacteremia or fungemia (15% for the ganciclovir group vs 15% for the placebo group, P = .67)

153 ified sepsis subgroup (ITT group: 23 days in ganciclovir group vs 20 days in the placebo group, P = .

154 up, P = .05; sepsis subgroup, 23 days in the ganciclovir group vs 20 days in the placebo group, P = .

155 on of mechanical ventilation (5 days for the ganciclovir group vs 6 days for the placebo group, P = .

156 P = .67), ICU length of stay (8 days for the ganciclovir group vs 8 days for the placebo group, P = .

157 reported in which hexadecyloxypropyl-phospho-ganciclovir (HDP-P-GCV) was used as a prototype.

158 resistance, compared with treatment with the ganciclovir implant alone (P=.023; Fisher's exact test).

159 fected eyes) with CMV retinitis treated with ganciclovir implant in the Division of Ocular Immunology

160 placebo, in 5 of 23 patients treated with a ganciclovir implant plus oral ganciclovir, and in 1 of 6

161 r a ganciclovir implant plus oral placebo, a ganciclovir implant plus oral ganciclovir, or intravenou

162 for cytomegalovirus retinitis with either a ganciclovir implant plus oral placebo, a ganciclovir imp

163 eral eyes of 0 of 28 patients treated with a ganciclovir implant plus oral placebo, in 5 of 23 patien

164 nal detachment, were relatively common after ganciclovir implantation but severe vision loss after su

165 mes and the effect of intraocular therapies (ganciclovir implants, intravitreal injections) on ocular

166 One hundred sixty-six eyes received 257 ganciclovir implants.

167 stem/progenitors at the time of injury with ganciclovir in a nestin-HSV-TK transgenic model, we elim

168 plant recipients receiving valganciclovir or ganciclovir in an international multicenter trial of CMV

169 evious studies, we also eliminated glia with ganciclovir in Gfap(HSV-TK) mice.

170 istered intratumorally or intravenously with ganciclovir in mice lacking a functional adaptive immune

171 inine butyrate and the antiherpes viral drug ganciclovir in the treatment of EBV lymphomas prompted u

172 rmacokinetic study of the use of intravenous ganciclovir in this population, a target AUC12 (area und

173 ptosis either during cell scratch healing or ganciclovir-induced apoptosis.

174 vitro and observational studies suggest that ganciclovir inhibits HHV-8 replication, but no randomize

175 ed, but encouraging, for example in cases of ganciclovir intolerance.

176 s, such as CMV-IgG-negative serostatus; (vi) ganciclovir intolerance; (vii) patients with hypogammagl

177 months of treatment of OD with intravitreal ganciclovir, intravitreal dexamethasone and systemic pre

178 w-volume, intermediate-dose (1.0 mg/0.02 ml) ganciclovir is an efficacious option in developing count

179 Furthermore, as the nucleoside analog ganciclovir is the current drug of choice for treating H

180 typically oral valganciclovir or intravenous ganciclovir) is now almost universal, at least in high-r

181 protein 70 (CMV-hsp70), along with systemic ganciclovir, kills normal melanocytes and raises a CD8+

182 associated with increased prior exposure to ganciclovir (median, 153 vs 91 days, P < .001).

183 eakpoint-dependent expression of EGFP-tk and ganciclovir-mediated apoptosis.

184 nd bystander cells synergistically increased ganciclovir-mediated cytotoxicity to both cell populatio

185 We found that ganciclovir-mediated microglial ablation on tga20/CD11b-

186 , intranucleotide hydrocarbon linkers, and a ganciclovir-modified deoxyribonucleotide.

187 who had received chemoprophylaxis with (val-)ganciclovir (n = 63), the CMV-free survival rates at 1 y

188 Therapy primarily involves ganciclovir, now rendered more versatile by data suggest

189 We did not observe a net effect of ganciclovir on PEL growth in culture or as xenograft.

190 nance dose of 1.0 mg/0.02 ml of intravitreal ganciclovir once weekly after standard induction therapy

191 st-CTL infusion) and 9 required therapy with ganciclovir or foscarnet (only 1 post-CTL infusion).

192 Antiviral treatment with ganciclovir or foscarnet was associated with improved ou

193 rculating neutrophils while receiving either ganciclovir or its prodrug valganciclovir.

194 for 5 days), followed by either intravenous ganciclovir or oral valganciclovir once daily until hosp

195 on of PELs with valproate in the presence of ganciclovir or PFA can selectively target tumor cells fo

196 old increase over baseline were treated with ganciclovir or valganciclovir (5 mg/kg or 900 mg twice d

197 ganciclovir following oral administration of ganciclovir or valganciclovir for prophylaxis of cytomeg

198 plantation in 263 patients who received oral ganciclovir or valganciclovir prophylaxis.

199 Doses of ganciclovir or valganciclovir were low in 10 (26%) of 39

200 ral placebo, a ganciclovir implant plus oral ganciclovir, or intravenous (iv) ganciclovir.

201 ate that, after induction with 14 days of IV ganciclovir, oral ganciclovir can be as effective as IV

202 ively; therefore, we used a thymidine kinase/ganciclovir paradigm to ablate both dividing NG2(+) cell

203 Sixteen of the ganciclovir patients (5.4%) and six of the valganciclovi

204 Furthermore, significantly fewer ganciclovir patients had EC-confirmed CMV disease or CMV

205 MV infections were similar for maribavir and ganciclovir patients.

206 onexpressing bystander cells via transfer of ganciclovir phosphates through gap junctions.

207 ed recently that they transfer low levels of ganciclovir phosphates to bystander cells.

208 Prolonged (val)ganciclovir plus CMVIG reduces viral levels, acute rejec

209 Ganciclovir prescribed for cytomegalovirus prophylaxis i

210 The antiviral drug ganciclovir prevents CMV disease in heart transplant pat

211 To assess the outcome of low-dose-ganciclovir prophylaxis (500 mg twice a day for 3 months

212 Both 24 weeks ganciclovir prophylaxis (O.R. 0.15, 95% C.I. 0.03-0.91,

213 to examine the relationship between 24 weeks ganciclovir prophylaxis and the odds of developing CMV i

214 One D+/R- cohort received ganciclovir prophylaxis for 14 days after transplantatio

215 Oral ganciclovir prophylaxis for 24 weeks is associated with

216 rine CMV (MCMV) renal transplantation model, ganciclovir prophylaxis improved innate infiltrates and

217 These results suggest that ganciclovir prophylaxis may have a long-term beneficial

218 Ganciclovir prophylaxis reduces allograft injury and NK

219 To determine whether ganciclovir prophylaxis reduces plasma interleukin 6 (IL

220 th a historical cohort of children receiving ganciclovir prophylaxis, PET did not differ from prophyl

221 All patients received 3 months of ganciclovir prophylaxis.

222 on, early postoperative enteral feeding, and ganciclovir prophylaxis.

223 inhibitor and a viral replication inhibitor, ganciclovir, represents a possible strategy to eliminate

224 loping CMV disease, there was no evidence of ganciclovir resistance and no mortality over a mean foll

225 e are used to assess the level of associated ganciclovir resistance and therapeutic options.

226 rs and outcomes attributable specifically to ganciclovir resistance appropriately be determined.

227 patients (22 SOT, 17 HCT), 15 had documented ganciclovir resistance mutations and 11 (28%) of 39 had

228 l number of patients (n=3 per arm) had known ganciclovir resistance mutations detected during viral b

229 ease, and disease severity without increased ganciclovir resistance or toxicity.

230 a rapid PCR- and sequencing-based assay for ganciclovir resistance that can be performed in 1 to 2 w

231 higher in HCT than SOT (P = 0.001), although ganciclovir resistance was more common in SOT (P = 0.003

232 Measured levels of ganciclovir resistance were closely comparable when assa

233 dence of an increased incidence of genotypic ganciclovir resistance when compared with those in the 1

234 , acute rejection, opportunistic infections, ganciclovir resistance, and safety.

235 located upstream of UL97 mutations linked to ganciclovir resistance, closer to kinase domains that ar

236 ath, other infections, resource utilization, ganciclovir resistance, quality of life, immune reconsti

237 d substitutions K599E and T601M conferred no ganciclovir resistance, while A591V conferred 3.8-fold-d

238 e codons conferred at least 8-fold-increased ganciclovir resistance, while the level of resistance co

239 th mutations associated with a high level of ganciclovir resistance.

240 served that were of unknown significance for ganciclovir resistance.

241 unistic infections, adverse events, CMV UL97 ganciclovir-resistance mutations, and laboratory abnorma

242 Ganciclovir-resistant (ganR) cytomegalovirus (CMV) is an

243 tion or recurrent disease, and patients with ganciclovir-resistant CMV infection or who are intoleran

244 Ganciclovir-resistant cytomegalovirus can cause disease

245 pediatric thoracic transplant patients with ganciclovir-resistant infection, or in serious or compli

246 Outcomes of existing treatment for ganciclovir-resistant or refractory CMV are suboptimal,

247 ose who had received foscarnet treatment for ganciclovir-resistant or refractory CMV infection.

248 resent study was to examine the emergence of ganciclovir-resistant virus in the contralateral eyes of

249 Only through direct comparison of ganR- and ganciclovir-sensitive (ganS) CMV infection can risk fact

250 sing cells, addition of hydroxyurea restored ganciclovir sensitivity.

251 Both acyclovir and ganciclovir statistically significantly prevented CMV or

252 The ganciclovir susceptibilities of 17 mutants in this codon

253 y uncharacterized genotypic changes affected ganciclovir susceptibility, especially in those receivin

254 individually confer 5- to 10-fold-decreased ganciclovir susceptibility, except that a 3-fold decreas

255 ion demonstrating a significant reduction in ganciclovir susceptibility.

256 phenotypic assay of the resulting virus for ganciclovir susceptibility.

257 V resistance without significantly affecting ganciclovir susceptibility.

258 substitutions were newly confirmed to alter ganciclovir susceptibility: A505V and I726T conferred a

259 ioretinitis, received localized and systemic ganciclovir, systemic cidofovir analog, and localized fo

260 poptosis were examined at 0, 4 and 8 days of ganciclovir/thymidine kinase gene therapy.

261 yme/prodrug systems such as thymidine kinase/ganciclovir (TK/GCV), yeast cytosine deaminase/5-fluoroc

262 We prospectively administered 24 weeks ganciclovir to 31 D+/R- recipients.

263 In contrast, administration of ganciclovir to Gfap(HSV-TK) mice eliminated fewer glia b

264 These mice were then treated with ganciclovir to specifically target only the vGPCR-expres

265 lants (8.3+/-0.9; P<0.01), which improved in ganciclovir-treated allografts (9.5+/-1.4).

266 cted grafts (P<0.05), which decreased in the ganciclovir-treated grafts.

267 Furthermore, ganciclovir-treated mice did not demonstrate abnormal pu

268 of viraemia (p=0.0480) and number of days of ganciclovir treatment (p=0.0287) were reduced in vaccine

269 Ganciclovir treatment following cecal ligation and punct

270 arrested tumour growth, and combined TMZ and ganciclovir treatment impeded tumour development.

271 beta-cells express a viral thymidine kinase, ganciclovir treatment induced hyperglycemia, providing a

272 Finally, ganciclovir treatment prevented pulmonary fibrosis follo

273 n situ and tumor killing by thymidine kinase/ganciclovir treatment, but neither strategy alone, provo

274 cells were purged from surviving mice after ganciclovir treatment.

275 Eight patients received ganciclovir treatment.

276 irus, as well as increased susceptibility to ganciclovir treatment.

277 P pool, which should lessen competition with ganciclovir triphosphate for DNA incorporation.

278 d dGTP pools without significantly affecting ganciclovir triphosphate levels.

279 ough hydroxyurea significantly increased the ganciclovir triphosphate:dGTP value for 12 to 24 hours i

280 a suggest that the prolonged increase in the ganciclovir triphosphate:dGTP value in cells in cocultur

281 3000 cytomegalovirus genomes per mL received ganciclovir until two consecutive undetectable cytomegal

282 on (hazard ratio=0.22, P=0.03) compared with ganciclovir usage.

283 the 3 months prior to the IFI, C. glabrata, ganciclovir use in the 3 months prior to the IFI, diabet

284 ugs are used for preventing or treating CMV: ganciclovir, valganciclovir, foscarnet, and cidofovir.

285 High-dose ganciclovir/valganciclovir can be an option in the treat

286 onsisted in all patients of antiviral drugs (ganciclovir/valganciclovir) combined with anti-CMV Ig fo

287 ppressed during prophylaxis when exposure to ganciclovir was 40-50 microg.h/ml, AUCs typical of those

288 after initiation of valganciclovir and oral ganciclovir was 80.5% versus 50.7% at 1 week, 99.5% vers

289 lovir, arginine butyrate in combination with ganciclovir was administered in 15 patients with refract

290 Ganciclovir was administered twice daily at standard dos

291 CMV resistance to foscarnet and ganciclovir was detected after only 6 and 11 weeks of th

292 TD for arginine butyrate in combination with ganciclovir was established as 1000 mg/(kg/day).

293 Low-dose ganciclovir was found to be as effective in decreasing t

294 The combination of arginine butyrate and ganciclovir was reasonably well-tolerated and appears to

295 of ganciclovir from valganciclovir and oral ganciclovir were 46.3 +/- 15.2 and 28.0 +/- 10.9 microg.

296 Both oral and IV ganciclovir were generally well tolerated.

297 who received antiviral prophylaxis with oral ganciclovir were retrospectively analyzed using Cox prop

298 end-organ disease can be prevented by giving ganciclovir when viraemia is detected in allograft recip

299 mparing sequential intravenous (IV) and oral ganciclovir with prolonged IV ganciclovir for long-term

300 and in 4 of 32 patients (12.5%) receiving IV ganciclovir within the first year after transplantation